The Way Judges and Legislators Interact
Whatever high minded pretense we might have carried about the separations of power has long gone. Trump proved that easy ...
How Healthcare Fixes the Ballot
Health policy might not make headline news, but it subtlety affects how candidates posture to their voters.
Careful When Reporting on Psychedelics Research or Legislation
Despite the hype, optimism and legislation involving the potential of psychedelics, researchers warn that there's much we don't know.
Patients Get Protection from Medical Debt
The Consumer Financial Protection Bureau has one priority: “looking out for people, not big banks, not lenders, not investment houses.”
India’s Influence on American Healthcare
It's fascinating to witness how diverse cultures such as India and America are converging to create similar healthcare models.
From Patient Advocate to Subject Matter Expert
Patient advocates are gaining prominence and increasingly becoming influential players in shaping health policy.
Fentanyl Now Cut With Horse Sedatives
Federal regulators approved the tranquilizer for animals in the early 1970s and it’s used to sedate horses for procedures like ...
TikTok Misexplains PTSD
A TikTok ‘expert’ says you have post-traumatic stress disorder − but do you? A trauma psychiatrist explains what PTSD really ...
A Medical Trail of Tears
Even when I was in the military during the first Gulf War, we were trained to treat the most injured ...
I Did a Week on Tinder
I created a Tinder account to monitor the spread of STIs. What I found instead was how social media manipulates ...
Cooking With a Chronic Illness
A Crockpot is my favorite cooking tool that helps me manage dinners for my husband and me. It’s an assistive ...
Healthcare Shrinkage
Healthcare's growing administrative burden may seem to signal a growing industry. In reality, it portends a period of contraction.
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more